Analyzing lung cancer risks in patients with impaired pulmonary function through characterization of gut microbiome and metabolites.
Jiahui LuanFuxin ZhangLijun SuoWei ZhangYige LiXiaofeng YuBo LiuHongyun Cao
Published in: BMC pulmonary medicine (2024)
Our results showed that microbiome and metabolomics analyses provide important candidate to be used as clinically diagnostic biomarkers and therapeutic targets related to lung cancer with impaired pulmonary function.